Avogaro, Angelo
 Distribuzione geografica
Continente #
NA - Nord America 474
EU - Europa 176
AS - Asia 56
AF - Africa 16
SA - Sud America 1
Totale 723
Nazione #
US - Stati Uniti d'America 468
IT - Italia 70
SE - Svezia 53
BG - Bulgaria 25
CN - Cina 20
SG - Singapore 20
FR - Francia 10
RU - Federazione Russa 9
SN - Senegal 9
DE - Germania 6
CA - Canada 5
CI - Costa d'Avorio 5
VN - Vietnam 5
IN - India 4
GB - Regno Unito 3
TR - Turchia 3
HK - Hong Kong 2
NG - Nigeria 2
AR - Argentina 1
IL - Israele 1
MX - Messico 1
MY - Malesia 1
Totale 723
Città #
Fairfield 71
Chandler 53
Houston 48
Woodbridge 48
Ashburn 44
Sofia 25
Seattle 22
Wilmington 20
Cambridge 18
Milan 18
Ann Arbor 17
New York 16
Beijing 13
Boulder 10
Dakar 9
Lawrence 9
Princeton 9
Singapore 9
Marseille 8
Dearborn 6
Abidjan 5
Des Moines 5
Florence 5
Ottawa 5
Rome 5
San Diego 5
Medford 4
Bremen 3
Frankfurt am Main 3
Nanjing 3
Norwalk 3
Thiruvananthapuram 3
Boardman 2
Bologna 2
Bolzano 2
Dong Ket 2
Hong Kong 2
Lagos 2
Los Angeles 2
Pisa 2
Serra 2
Washington 2
Acton 1
Bristol 1
Buenos Aires 1
Costermano 1
Dundee 1
Haikou 1
Hebei 1
Istanbul 1
Kocaeli 1
Massa 1
Melaka 1
Monterrey 1
Ogden 1
Piediluco 1
Redwood City 1
Shenyang 1
Somerville 1
Volargne 1
Watchung 1
Totale 561
Nome #
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial 172
A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus 112
Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome 81
The use of real time continuous glucose monitoring or flash glucose monitoring in the management of diabetes: A consensus view of Italian diabetes experts using the Delphi method 75
Reinterpreting Cardiorenal Protection of Renal Sodium-Glucose Cotransporter 2 Inhibitors via Cellular Life History Programming 72
Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus 68
Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study 53
null 44
Effects of pioglitazone versus glyburide on endothelial function in type 2 diabetic patients with vascular complications: the SPLENDOR Study 34
Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study 32
Totale 743
Categoria #
all - tutte 2.386
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.386


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020183 17 18 5 8 12 24 22 22 23 10 17 5
2020/202194 4 8 7 4 12 6 9 6 11 9 7 11
2021/2022102 3 5 0 5 30 10 3 7 6 11 3 19
2022/2023167 19 20 16 5 20 20 1 12 40 1 7 6
2023/202496 5 8 18 9 14 20 2 4 1 4 1 10
Totale 743